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https://doi.org/10.1016/j.jacl.2017.11.0BACKGROUND: For children with familial hypercholesterolemia (FH), UK guidelines recommend
consideration of statin therapy by age 10 years and dietary and lifestyle advice to maintain an ideal
body weight.
OBJECTIVES: The objective of the study is to use the UK Paediatric Familial Hypercholesterolemia
Register to determine: (1) the prevalence of plasma markers of liver toxicity and muscle damage in
statin-treated FH children; (2) the prevalence of obesity in FH children compared to the UK general
population; and (3) to compare growth rates in statin-treated and nontreated children.
METHODS: Differences in registration and 1-year characteristics were compared by Mann-Whitney
U tests. Age and gender body mass index percentiles were compared to UK children’s growth charts.
RESULTS: In 300 children (51% boys, 75% Caucasian, untreated mean [standard deviation] low-
density lipoprotein cholesterol 5.50 [1.49] mmol/L), the proportion on statins varied significantly
(P , .005) by age group (,5 years 5 0%, 5–10 years 5 16.7%, 10–15 years 5 57.1%, and
.15 years 5 73.2%). Statin treatment reduced low-density lipoprotein cholesterol by 31% (1.84
[1.43] mmol/L), and no child showed elevated levels of markers of liver toxicity or muscle damage.
At registration, 16.9% of the FH children were overweight (.85th percentile) and 11.1% were obese
(.95th percentile) vs reported in 21.2% in UK non-FH children. There was no difference in annual
growth rate in statin vs no-statin groups (age-adjusted weight increases 3.58 vs 3.53 kg; P5 .91, height
4.45 vs 4.60 cm P 5 .73).pported by funds from the British
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26 Journal of Clinical Lipidology, Vol 12, No 1, February 2018CONCLUSIONS: We show no evidence for statin-related safety or growth issues, but many FH chil-
dren over the age of 10 years are not on statin treatment. Fewer UK children with FH are obese
compared to UK non-FH children.
 2017 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Familial hypercholesterolemia (FH) is an autosomal
dominant inherited disorder characterized by elevated
low-density lipoprotein cholesterol (LDL-C) levels from
birth,1 with premature coronary heart disease (CHD) occur-
ring in roughly half of men by age 50 years and one-third of
women by age 60 years.2 Statin therapy has been shown to
significantly reduce CHD risk in FH patients.2 Although
historically the prevalence of heterozygous FH (HeFH) is
thought to be 1 in 500, recent studies have indicated the
prevalence of HeFH in the United Kingdom and in coun-
tries in Europe may be twice as high.3–5 The underlying
genetic cause for FH is most often due to mutations within
the LDLR gene, which encodes the low-density lipoprotein
receptor, but mutations in apolipoprotein B and proprotein
convertase subtilisin/kexin type 9 can produce a phenotype
identical to LDLR FH.6 In patients in whom no causative
mutation can be found, a polygenic cause of their hyperlip-
idemia is most likely.7,8 The detection of the causative
mutation in a proband allows cost-effective DNA-based
‘‘cascade testing’’ in the family members, and this approach
is recommended in most FH guidelines.1,9–13 Once
identified, the subjects with FH can be offered healthy
lifestyle advice (eg, avoiding or stopping smoking) and
lipid-lowering therapies.
All recent guidelines for the identification and manage-
ment of adults and children with FH1,9–13 have recommen-
ded the use of lipid-lowering statin therapy in children. In
the United Kingdom, the 2008 NICE guideline (CG71) rec-
ommends that statin therapy should be considered by the
age of 10 years. In the United Kingdom, atorvastatin is
licensed in children over the age of 10 years up to a dose
of 20 mg per day, whereas pravastatin is licensed from
the age of 8 years with doses of 10–20 mg per day and
in older children up to 40 mg daily.14 Recent European
guidelines on the management of FH in childhood proposed
that LDL-C be lowered below 3.5 mmol/L if possible.13
However, the age at which statin use should be started, or
its intensity to best prevent the onset of adult premature
CHD has not been rigorously established because there
are no long-term randomized controlled outcome trials
for ethical reasons. Encouragingly, a recent study indicated
that initiating statin therapy in childhood resulted in fewer
CHD events at a young age than had been seen historically
in the parents.15 There is however considerable short-term
randomized and observational data on the utility of statin
therapy in children with HeFH, showing a good safety
profile, without liver toxicity side effects, no influence ongrowth trajectory and excellent efficacy in terms of LDL-
C reduction over periods of 2–3 years.16,17 Where it has
been examined, there have been no reports of significant in-
crease in muscle pain and/or plasma levels of creatine
kinase when on statins.
FH management guidelines, including the UK NICE
guideline, recommend that all children (and adults) with
HeFH should adopt healthy eating habits, be physically
active, and make sensible lifestyle choices, to maintain an
ideal body weight.1,9–13 There is much current concern
about the development of obesity in children, with the sub-
sequent influence on morbidity, and a recent study of the
Millennium children reported that between 11.8%–14.6%
of 5- to 11-year-old UK children are overweight (body
mass index [BMI] . 85th percentile) with 11.9%–21.2%
being obese (BMI .95th percentile).18 We are unaware
of any comparable data in UK FH children.18
The UK National Paediatric Familial Hypercholestero-
laemia Register was established in 2012 to collect baseline
and long-term follow-up data on all children with HeFH in
the United Kingdom. We have previously published
baseline data on a subset of these children, which
demonstrated that treatment decisions in children with
HeFH are appropriately based on a stronger family history
of CHD and higher LDL-C.19 Here, we determined the
prevalence of elevated levels of markers of liver toxicity
and muscle damage in statin-treated children as an indica-
tor of statin damage and examined the hypothesis that
because of the dietary and lifestyle advice they receive,
the prevalence of obesity in this cohort of FH children
will be lower than that in the general population and that
the growth rate from annual follow-up data will be similar
in statin-treated and nontreated children.Methods
All lipid clinics in the United Kingdom and pediatricians
with an interest in lipid disorders were contacted electron-
ically and details of the register provided. An electronic
web-based data capture tool was developed to collect
information. The register captures routine clinical data,
demography, family history, treatment, and lifestyle details,
and clinicians are sent an electronic reminder to fill in
annual follow-up data. Full details of the establishment and
governance of the register have been published,19 as well as
the data fields included in the electronic web-based data
capture. UK ethical approval was obtained in November
2012 from the NRES Committee North East–Newcastle
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consent was obtained from the parents or guardians of the
children who were mentioned on the register and, where
appropriate, assent was obtained from the children. Patient
information sheets, age-specific consents and assents, and
parent information leaflets are available from the authors
on request. Children were diagnosed as having FH based
on the UK Simon Broome criteria,2 with the majority
having been identified by family studies from an index
case with a clinical diagnosis of FH. Of the children,
98.7% (232/235) have a diagnosis of HeFH, whereas 3 in-
dividuals had a total cholesterol .15 mmol/L compatible
with a diagnosis of homozygous FH and were excluded
from the analysis. For annual review, the most recent age,
weight, height, plasma lipid profile, type and dose of statin
if prescribed, and values of creatinine kinase (CK), alanine
aminotransferase (ALT), and aspartate aminotransferase
(AST) reported as part of routine clinical care were
analyzed. Statin-induced toxicity was examined as the pro-
portion of children having levels over 2.5 times the upper
limit of normal as described in the Common Terminologies
Criteria for Adverse Events guidelines.
Statistical methods
Results for continuous variables are presented as mean
(6standard deviation) and median (with interquartile
range), and differences by sex and statin use are tested
using Mann-Whitney U tests. The BMI was calculated as
(mass in kg)/(height in m)2. Age- and gender-specific
BMI percentiles were calculated using the childhood BMI
batch calculator https://www.cdc.gov/healthyweight/xls/
bmi_group_calculator_english.xls.
Only those with both recorded weight and height were
included. Differences in the prevalence of overweight and
obesity were examined using a 2 ! 2 chi-squared test.
Differences in BMI height, weight, and the fall in LDL-C
by statin use are adjusted for age using analysis of
covariance. Changes in BMI weight and height were
calculated as change per 1-year increase in age and are
based on those with at least 1 year of follow-up, whereas
changes in lipid levels are the difference between the
follow-up and registration. Categorical variables are
presented as percentages and number and tested using
chi-squared tests or Fisher’s exact test. Changes in LDL-C
by statin use were analyzed using analysis of covariance
with adjustment for age and length of follow-up. For
conversion to mg/dL, mmol/L levels of total and LDL-C
should be multiplied by 38.7.Results
Baseline data shown in Table 1 include 300 HeFH
children (51% boys, 75% Caucasian), with an untreated
mean (SD) LDL-C of 5.50 (1.49) mmol/L. After a mean
(SD) duration of follow-up of 2.7 (2.4) years, overall52.5% of the children were on statins at follow-up, but this
varied significantly (c25 34.6 P, .005) by age group, being
0% (0/2) in those under 5 years, 16.7% (7/42) in those
between 5 and 10 years, 57.1% (80/140) in those between
10 and 15 years, and 73.2% (41/56) in those over 15 years
(Online Fig. 1). In children both below and above the age
of 10 years, LDL-C was significantly higher prior to
commencing statins than in the untreated cohorts, LDL-C
of 5.88 (1.49) mmol/L vs 5.21 (1.42) mmol/L (P 5 .0004),
respectively, and those on statins also had stronger evidence
of a family history of early CHD (overall 43.7% vs 32.7%;
P 5 .05). The proportion of children with a reported
FH-causing mutation was not significantly different in treated
and nontreated children (66% vs 68%; P 5 .77).
As shown in Online Table 1, the commonly used statins
were atorvastatin (49.2%; n 5 63), pravastatin (27.3%,
n 5 35), simvastatin (21.1%; n 5 27), and rosuvastatin
(2.3%; n 5 3). There was no significant difference in age
at treatment (P 5 .46) in those on different statins (means
[ranges]) for age at treatment: pravastatin 11.2 (6–15), ator-
vastatin 12.0 (7–18), and simvastatin 12.5 (6–17). A small
proportion of patients were on resins (2.2%), and 1 patient
was reported to be on ezetimibe. No patients were on
fibrates, and the use of plant stanols was limited (1.6%,
n 5 2). As shown in Online Table 2, in those on statin treat-
ment, LDL-C levels were reduced compared to the diag-
nostic values by 31% (mean 5 1.84 (SD 5 1.43) mmol/
L), and this reduction was slightly greater in those with no
detected mutation compared to those with a detected muta-
tion (36% [mean 5 2.26 {SD 5 1.50}] vs 27% [mean 5
1.55 {SD 5 1.38}] mmol/L, P 5 .04). This appears to be
due to the higher baseline levels in those with no detected
mutation because mean on-treatment levels were similar in
both groups (Online Fig. 2). In the treated group, 55.6% still
had levels over the suggested target of 3.5 mmol/L.
Finally, we examined the characteristics of the children
over the age of 10 years, which is the age by which the UK
NICE FH guideline and the European consensus guide-
lines13 recommend that initiation of statin therapy should be
considered. As shown in Table 2, in this group (n 5 71),
35% had evidence of a family history of early CHD, with
the mean age of onset of CHD in any relative of 44.8 years,
and 62% of the children carried an FH-causing mutation.
As shown in Online Figure 3, 82.3% (56/68 with diag-
nostic LDL-C recorded) had LDL-C over 3.5 mmol/L. In
the 102 children over 10 years not on statins, no reasons
were recorded for 20 children, but as shown in Online
Table 3, in those giving a reason, 37.2% were because
the clinician considered the risk was low, 31.4% were
attending their first clinic visit, awaiting DNA or repeat
lipid measures, and were trying dietary measures, and
14% were being started on a statin after the current clinic
visit. In only 12.8% was the reason given that the parent
or patient had declined, and only 2.3% were due to statin
intolerance in the patient (or parent).
We addressed the issue of the safety of statin use by
analyzing the measures of plasma CK, ALT, and AST at
Table 1 Characteristics at diagnosis by statin use
No statin use (N 5 165) Statin use (N 5 135) P value
Age, y
Mean (SD); N 9.5 (3.5); 165 10.7 (3.2); 135 .001
Median (IQR) 9.5 (6.8–12.3) 10.8 (8.9–13.4)
Sex
% Male 51.5% (85/165) 50.4% (68/135) .84*
Ethnicity
% Caucasian 77.6% (128/165) 71.9% (97/135) .26*
Smoking, % (N) 1.23% (2/162) 1.5% (2/132) 1.00
Mutation status
% Yes (number) 67.8% (101/149) 66.1% (84/127) .77*
CHD in parent/first-degree relative
% Yes 18.2% (30/165) 24.2% (32/132) .20*
CHD in any relative
% Yes 32.7% (54/165) 43.7% (59/135) .05*
CHD onset age in relative
Mean (SD); N 40.8 (15.4); 54 38.3 (14.7); 59 .38
Median (IQR) 41 (36–51) 40 (34–46)
Weight (kg)
Mean (SD); N 37.4 (17.4); 150 42.1 (18.1); 121 .02
Median (IQR) 33.8 (23.5–48.8) 40.5 (28.5–51.9)
Height (m)
Mean (SD); N 1.37 (0.22); 141 1.45 (0.19); 107 .004
Median (IQR) 1.37 (1.22–1.55) 1.48 (1.32–1.59)
BMI (kg/m2)
Mean (SD); N 1918.6 (4.2); 141 19.2 (4.3); 107 .09
Median (IQR) 17.0 (15.6–20.9) 18.6 (16.2–21.1)
Cholesterol (mmol/L)
Mean (SD); N 7.15 (1.47); 165 7.79 (1.49); 135 .0003†
Median (IQR) 7.1 (6.2–8.1) 7.7 (6.8–8.7)
HDL-C (mmol/L)
Mean (SD); N 1.41 (0.34); 154 1.38 (0.30); 127 .70
Median (IQR) 1.36 (1.2–1.6) 1.4 (1.2–1.6)
Triglyceride (mmol/L)
Mean (SD); N 1.02 (0.52); 150 1.06 (0.56); 125 .47
Median (IQR) 0.8 (0.7–1.3) 0.9 (0.7–1.3)
LDL-C (mmol/L)
Mean (SD); N 5.21 (1.42); 158 5.88 (1.49); 123 .0004‡
Median (IQR) 5.1 (4.2–6.1) 5.8 (4.8–6.8)
CHD, coronary heart disease; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SD,
standard deviation; IQR, interquartile range.
*Wilcoxon tests were used to compare continuous variables between statin treatment groups, whereas chi-squared tests were used for categorical
variables.
†Age-adjusted P value 5 7.5 ! 1026.
‡Age-adjusted P value 5 2.1 ! 1026.
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levels of CK, ALT, or AST indicative of statin toxicity (ie,
. 2.5 times the normal range (Online Table 2 and Online
Fig. 4)). Muscle pain was not recorded routinely in the
register. However, in our experience and anecdotally, mus-
cle symptoms in children taking statins are rare, usually
mild, and resolve over a short period of time after starting
statins. We are not aware of any patients on the register
having reported statin-induced rhabdomyolysis.Online Figure 5A shows the baseline distribution of BMI
by age, with the expected increase as children get older. As
shown in Figure 1A, using BMI 25–30 kg/m2 as a measure
of overweight and BMI .30 kg/m2 as obese, at diagnosis,
7.0% (17/243) would be classified as overweight and 2.1%
(5/243) as obese. However, these BMI cutoffs are not
appropriate for use in children.
The age- and gender-specific percentiles are used, with a
BMI at or above the 85th percentile being designated as
Table 2 Characteristics at diagnosis in those over 10 years
without statin use (n 5 71)
Age (y)
Mean (SD) 12.79 (1.84)
Median (IQR) 12.57 (10.9–14.1)
Sex
% Male 47.9 (34/71)
Ethnicity
% Caucasian 76.1 (54/71)
Smoking, % (N) 2.9% (2/69)
Mutation status, % (N) 61.7% (37)
CHD in parent/first-degree relative
% Yes 18.3% (13/71)
CHD in any relative
% Yes 35.2% (25/71)
CHD onset age in relative
Mean (SD) 44.8 (11.5)
Median (IQR) 46 (20–64)
Weight (kg)
Mean (SD) 51.8 (14.5)
Median (IQR) 49 (42–59.4)
Height (m)
Mean (SD) 1.57 (0.12)
Median (IQR) 1.56 (1.49–1.63)
BMI (kg/m2)
Mean (SD) 21.0 (4.4)
Median (IQR) 20.6 (17.8–23.7)
Cholesterol (mmol/L)
Mean (SD) 6.72 (1.37)
Median (IQR) 6.6 (5.8–7.5)
HDL-C (mmol/L)
Mean (SD) 1.44 (0.36)
Median (IQR) 1.40 (1.2–1.65)
Triglyceride (mmol/L)
Mean (SD) 1.08 (0.54)
Median (IQR) 0.9 (0.7–1.3)
LDL-C (mmol/L)
Mean (SD) 4.75 (1.31)
Median (IQR) 4.65 (3.85–5.5)
LDL-C .3.5 mmol/L, % (N) 82.3% (56)
CHD, coronary heart disease; BMI, body mass index; HDL-C, high-
density lipoprotein cholesterol; LDL-C, low-density lipoprotein choles-
terol; SD, standard deviation; IQR, interquartile range.
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The age and gender percentile distribution is shown in
Figure 1B, with 16.9% being overweight and 11.1% being
obese. Compared to data from a large UK survey of non-FH
children,18 the prevalence of overweight was similar
(14.6% vs 16.9%; P 5 .33), but the prevalence of obesity
was significantly lower (22.1% vs 11.1%; P 5 .0002).
In the annual review data (Online Fig. 5B), 17.6% had a
BMI percentile indication of overweight and 11.9% as
obese (not significantly different from the proportions
seen at diagnosis). Changes in height and weight were
calculated as change per 1-year increase in age and were
based on those with at least 1 year of follow-up. As shownin Table 3, there was no significant difference in the in-
crease in weight or height in those being statin treated
compared with those not on statins (P 5 .91 and P 5 .73,
respectively, after adjustment for age at diagnosis and sex).Discussion
The main findings of this report are that, reassuringly,
annual follow-up data showed no difference in average
growth rate in the statin-treated children compared to the
no-statin children, and none of those on statin had a
clinically significant increase in measured plasma levels
of CK, ALT, and AST, showing no evidence of any statin
toxicity. From this perspective, our data are in keeping with
the published short-term safety profile of statins in children
(reviewed in the studies by Vuorio et al,16 Vuorio et al,17
and Emerson et al20). The long-term safety profile of statins
in adults is well established.21,22 The recent Dutch study re-
porting no CHD events in a 25-year follow-up of their
treated children cohort, and evidence of greater longevity
in the children than their FH parents,15 is supportive of
the value of early statin therapy.
As a consequence of the elevated LDL-C seen in
children with HeFH from birth, by the age of 10 years,
they develop atherosclerosis, detectable as a significant
degree of carotid intima-media thickness as compared with
their non-FH siblings.23,24 In a randomized controlled trial
of the use of pravastatin, further increase in carotid intima-
media thickness was prevented.25 Based on these data, the
NICE guideline (CG71) and the European consensus guide-
lines13 state that the use of statins should be considered in
children with HeFH by the age of 10 years using clinical
judgment, based on the child’s LDL-C level, age of onset
of CHD in the parent or relatives, and presence of other
CHD risk factors. The recent European expert opinion
guideline13 suggested that in childhood, an on-treatment
target LDL-C of 3.5 mmol/L would be ideal. Although
there is no RCT or long-term follow-up of children to sub-
stantiate this target as actually having benefit in terms of
CHD reduction, it is widely believed that such a therapy
would prevent the development of significant atheroscle-
rotic disease and subsequent cardiovascular events. In the
register, there are 34 boys and 37 girls above the age of
10 years where statin therapy has not been initiated. Of
these, over 80% have LDL-C over 3.5 mmol/L, and 35%
have evidence of early CHD in a first-degree relative. As
such, these children would be strong candidates for statin
treatment. In the statin-treated children, LDL-C levels had
been lowered by an average of 31% compared to the diag-
nostic level. However, 55.6% (75/135) still had levels over
the suggested target of 3.5 mmol/L. From experience, we
are aware that in some cases, this is due to poor adherence
(eg, in adolescence), and the register does not specifically
collect information on noncompliance. It could also be
due to a clinical decision to postpone, as a parental, child,
or clinician choice, the uptitration of statin dose for safety
Figure 1 Distribution of (A) BMI and (B) age and gender BMI percentile in 243 FH children. (A) 17/243 5 7% had a BMI between 25
and 30 kg/m2 (light stipple bars) and 5/2435 2.1% had a BMI. 30 kg/m2 (dark stipple bars). (B) 41/2435 16.9% had an age- and gender-
adjusted BMI percentile .85th percentile (light stipple bar) and 27/243 5 11.1% had an age- and gender-adjusted BMI percentile .95th
percentile (dark stipple bar). BMI, body mass index; FH, familial hypercholesterolemia.
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compare a noninvasive measure of subclinical atheroscle-
rosis such as by determining carotid intima-media thickness
in the treated and nontreated children in the register, but
unfortunately, such measures are not routinely carried out
in pediatric clinics and we have no data to address this.
The register collects data on reasons for not starting
statin therapy, and this has allowed us to explore to what
extent this could be due to reluctance from either clinicians
or parents, for example, because of misconceptions on the
longer term safety of statins when started in childhood. In
14% of cases, the records indicate that the child was being
started on statin at the current clinic visit,17 whereas in 37%
of cases, the recorded reason was because the clinician
considered the child to be at low future risk, and in 31% be-
ing due to the child being registered at the first clinic visit,
or with DNA testing or repeat lipid measures not having
been completed. Follow-up studies will enable us to docu-
ment what proportion of these children does indeedTable 3 Change in height and weight by statin use
No statin use
Change in weight (kg)
Mean (SD); N 3.50 (2.29); 65
Median (IQR) 3.39 (2.16–5.04)
After adjustment for
age at diagnosis and
sex [mean (SD); N]
3.53 (2.42); 65
Change in height (cm)
Mean (SD); N 4.87 (2.63); 46
Median (IQR) 5.27 (3.89–6.42)
After adjustment for
age at diagnosis and
sex [mean (SD); N]
4.60 (2.17); 46
Changes are calculated as change per 1-year increase in age and are basedcommence statin therapy. Only in 13% of children was
this due to nonconsent from the parent and in less than
2% was this due to statin intolerance.
The second main finding is that the BMI distribution in
these HeFH children identifies that a lower proportion of
children are obese compared to the UK general population,
whereas 16.9% of the HeFH children had a BMI suggestive
of being overweight, which is not significantly different for
the 14.6% reported in w14,000 non-FH UK children,18
only 11.1% were obese, which is roughly half the propor-
tion seen in non-FH UK children, where 21.2% were obese
by the age of 11 years. All FH guidelines recommend a
healthy low-fat diet and exercise lifestyle as part of the
management program for children (and adults) with FH,
and it appears that this advice is being followed in the chil-
dren seen here. None of the children have type I or type II
diabetes (T2D). One of the potential long-term side effects
of statin treatment in children with FH that needs to be
considered is the higher risk of developing T2D that hasStatin use P value
3.61 (2.52); 80 .97
3.34 (2.02–5.15)
3.58 (2.41); 80 .91
4.26 (2.39); 64 .14
4.49 (2.72–5.94)
4.45 (2.16); 64 .73
on those with at least 1 year of follow-up.
Humphries et al UK children’s FH register 31been noted in statin treatment of non-FH patients. A meta-
analysis of published RCTs in over 91,000 high-risk
patients from the general population26 reported that statin
therapy was associated with a 9% increase in the likelihood
of new T2D during follow-up. Reassuringly, many studies
have reported that the prevalence of T2D is low in adults
with FH and in a study of over 63,000 subjects from
Holland,27 even in treated adults, with FH the prevalence
of T2D was significantly lower than in their unaffected rel-
atives (1.75% vs 2.93%). Follow-up studies in adults28 and
children29 are also reassuring, with a 10-year follow-up in
194 statin-treated children (mean age at baseline 13 years)
seeing 1 new case of T2D, with a similar incidence in their
83 non-FH siblings.29 It would be of interest to examine
whether there is any impact on glycemia in the treated chil-
dren, but such tests are not routinely carried out in pediatric
clinics and we have no data to address this.
The main strength of the register data is that it is a
representative sample of children with FH who are being
treated in pediatric and adult lipid clinics in the United
Kingdom. Overall 67% of the children have a documented
FH-causing mutation and have mostly been identified by
cascade testing from an affected parent. Although some
parents may not have consented to a genetic test, the most
common reason for such tests not being carried out in
children is due to the poor availability of funding of such
tests in many parts of the country. The characteristics of the
children are similar to that observed in the 2010 UK
national audit of FH patients where notes on 147 children
were examined (https://www.rcplondon.ac.uk/projects/
outputs/familial-hypercholesterolaemia-audit). The vast
majority of the children on the register have been identified
by family studies from an index case with early CHD or
elevated cholesterol levels, and as far as we are aware,
none have been identified through lipid testing during
childhood; they are therefore likely to be more severely
affected than children detected, for example, by a national
screening program.4 However, based on the age distribution
in the United Kingdom and a prevalence of w1/250, there
may be up to 56,000 children under the age of 18 years in
the United Kingdom with FH, and it is clear that the major-
ity of children with FH have yet to be diagnosed.
In conclusion, this longitudinal analysis of children on
the UK FH register shows that the statin use in children is
not associated with any reductions in growth rate and is
safe in childhood, with no biochemical evidence of toxicity
over a 2- to 3-year period. There appears therefore to be no
contraindication to use statin lipid-lowering therapy in
children with FH, who are very likely to show a significant
long-term benefit in reduction in risk of future CHD.Acknowledgments
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